Scott Stoerner, MD
Rheumatology · Albuquerque, NMNPI 1053507715
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,917 of the $5,461 with a category attached, or 71.7%. 25 manufacturers reported payments, led by Boehringer Ingelheim at 25.1% of the total. Reporting peaked in 2020 at $1,582 and has fallen 52.7% since, to $748 in 2025.
Across 227 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- AbbVie$979
- UCB, Inc.$596
- Amgen$540
- Johnson & Johnson$465
- AstraZeneca$317
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,30024%
- Food & beverage$3,91772%
- Education$2444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $1,369 |
| AbbVie | 75 | $979 |
| UCB, Inc. | 26 | $596 |
| Amgen(2 entities) | 23 | $540 |
| Johnson & Johnson | 24 | $465 |
| AstraZeneca(2 entities) | 17 | $317 |
| Genentech USA, Inc. | 10 | $186 |
| Novartis | 8 | $157 |
| Sobi, Inc | 6 | $148 |
| GSK | 5 | $101 |
| Pfizer | 5 | $88 |
| Gilead | 4 | $87 |
| Sanofi-aventis U.S. LLC | 2 | $77 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $54 |
| Organon | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Sandoz | 1 | $28 |
| Pacira Therapeutics, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Biocon Biologics Inc | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Sanofi | 1 | $18 |
| Merck | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,300
How this compares
$5,461 in reported general payments places this provider in the 75th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 97 | $776,849 |
| Humira(Cf) PenAdalimumab | 33 | $368,190 |
| Xeljanz XrTofacitinib Citrate | 51 | $314,881 |
| StelaraUstekinumab | 12 | $259,940 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 23 | $166,087 |
| EnbrelEtanercept | 15 | $157,732 |
| OrenciaAbatacept | 19 | $113,651 |
| RinvoqUpadacitinib | 15 | $106,671 |
| KineretAnakinra | 13 | $71,196 |
| OtezlaApremilast | 13 | $62,457 |
| Orencia ClickjectAbatacept | 11 | $62,155 |
| Hydroxychloroquine Sulfate | 410 | $14,333 |
| Hadlima(Cf) PushtouchAdalimumab-Bwwd | 13 | $13,035 |
| MethotrexateMethotrexate Sodium | 393 | $9,309 |
| Mycophenolate Mofetil | 92 | $6,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $465 | $259,94012 claims |
| AmgenEnbrel, Otezla | $540 | $220,18828 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $33 | $113,65119 claims |
| AbbVieRinvoq | $979 | $106,67115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Albuquerque
- Wilmer SibbittAlbuquerque$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
- Andres PeisajovichAlbuquerque$4K
- Sabeen YaqubAlbuquerque$4K
- Mirza BegAlbuquerque$4K
- Ahsan IqbalAlbuquerque$3K
- Peter RosandichAlbuquerque$2K
- Juliet CoquiaAlbuquerque$2K
- Jacqueline DeanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.